Obesity Drug War Goes Global
The race for weight-loss drugs is intensifying as Chinese biotech firms accelerate development of GLP-1 alternatives, with Hua Medicine already securing approval for a new oral drug in Hong Kong. Meanwhile, Eli Lilly is eyeing a spring launch for its own oral weight-loss pill in the US, signaling a new, highly competitive phase for the multi-billion dollar market.
The global market for GLP-1 agonist drugs, the class of medications behind Ozempic and Wegovy, was valued at over $60 billion in 2025 and is projected to exceed $200 billion by the early 2030s. This explosive growth is fueled by the drugs' effectiveness in treating both type 2 diabetes and obesity, with North America currently representing the largest market share. Denmark's Novo Nordisk pioneered this market with its semaglutide products, Ozempic and Wegovy, which together generated over $18 billion in revenue in 2023. The company holds a commanding 55.1% of the GLP-1 market. However, surging demand has led to persistent supply shortages, creating a significant opportunity for competitors to enter the space. Eli Lilly has emerged as a formidable rival with its tirzepatide franchise (Mounjaro and Zepbound), which surpassed all other drugs to become the world's top-seller in 2025. Its new oral drug, orforglipron, has shown superior weight loss in head-to-head trials against Novo Nordisk's oral alternative, Rybelsus, and notably does not require being taken on an empty stomach. The competitive landscape is rapidly expanding in Asia, with more than 60 GLP-1 drugs now in development across China. This push is intensified by the looming 2026 expiration of Novo Nordisk's patent for semaglutide in the country, which is expected to open the floodgates for generic and biosimilar versions from companies like Jiuyuan Gene and Huadong Medicine. Hua Medicine's newly approved drug, dorzagliatin, represents a different approach. It is a first-in-class glucokinase activator (GKA) that, among other actions, promotes the body's own release of GLP-1. Already prescribed to over 200,000 patients in mainland China, its approval in Hong Kong signals a new front in the global competition, focusing on alternative mechanisms of action. Manufacturing these complex biologic drugs presents a major bottleneck for all players. The process is difficult and expensive to scale, leading to shortages and straining the global "fill-finish" capacity, where drugs are put into vials or pens. This production race is as critical as the R&D race, as companies invest billions to build and acquire new facilities to meet the unprecedented demand.
